Clinical Trials Browser

Active not recruiting × Breast Neoplasms × Tamoxifen × Clear all

NCT05780567 2026-04-17

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT00310180 2026-04-13

TAILORx

Phase 3 Active not recruiting

10,273 enrolled 14 charts

Breast Neoplasms

NCT02311933 2026-04-13

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Active not recruiting

81 enrolled 9 charts

Breast Neoplasms

NCT04569747 2026-04-02

ADEPT

Phase 2 Active not recruiting

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

Breast Neoplasms

NCT05514054 2026-04-02

EMBER-4

Phase 3 Active not recruiting

Breast Neoplasms

NCT01674140 2026-02-10

e3

Phase 3 Active not recruiting

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02747004 2026-02-06

Next MONARCH 1

Phase 2 Active not recruiting

234 enrolled 20 charts

Breast Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

Breast Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Phase 2 Active not recruiting

53 enrolled 13 charts

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT04906395 2026-01-13

OVELIA

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT05150652 2026-01-07

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT01196936 2026-01-05

LDTam

Phase 2 Active not recruiting

84 enrolled 17 charts

Breast Neoplasms

NCT04272801 2025-10-22

POWER

Phase 2 Active not recruiting

84 enrolled 9 charts

Breast Neoplasms

NCT04134598 2025-08-29

EUROPA

Phase 3 Active not recruiting

Breast Neoplasms

NCT05463601 2025-05-14

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT02764541 2025-05-07

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Phase 2 Active not recruiting

195 enrolled 26 charts

Breast Neoplasms, Carcinoma, Lobular

NCT03161353 2025-04-23

PHERGain

Phase 2 Active not recruiting

Breast Neoplasms

NCT01357772 2023-07-17

TAM-01

Phase 3 Active not recruiting

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Neoplasm Recurrence, Local

NCT02603679 2021-08-03

PREDIX LumB

Phase 2 Active not recruiting

Breast Neoplasms

NCT02592083 2020-07-07

PREDIX LumA

Phase 2 Active not recruiting

Breast Neoplasms